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Summary
Dubin-Johnson syndrome (DJS) is an autosomal reces-
sive disease characterized by conjugated hyperbilirubin-
emia. Previous studies of the defects in the human can-
alicular multispecific organic anion transporter gene
(MRP2/cMOAT) in patients with DJS have suggested
that the gene defects are responsible for DJS. In this
study, we determined the exon/intron structure of the
human MRP2/cMOAT gene and further characterized
mutations in patients with DJS. The human MRP2/
cMOAT gene contains 32 exons, and it has a structure
that is highly conserved with that of another
ATP–binding–cassette gene, that for a multidrug resis-
tance–associated protein. We then identified three mu-
tations, including two novel ones. All mutations iden-
tified to date are in the cytoplasmic domain, which
includes the two ATP-binding cassettes and the linker
region, or adjacent putative transmembrane domain.
Our results confirm that MRP2/cMOAT is the gene re-
sponsible for DJS. The finding that mutations are con-
centrated in the first ATP-binding–cassette domain
strongly suggests that a disruption of this region is a
critical route to loss of function.
Introduction
Dubin-Johnson syndrome (DJS) (MIM 237500), origi-
nally described in 1954 (Dubin and Johnson 1954), is
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an autosomal recessive disorder characterized by a defect
in the transfer of endogenous and exogenous anionic
conjugates from hepatocytes into the bile. This defect
results in predominantly conjugated hyperbilirubinemia
and a characteristic secondary rise of intravenously in-
jected sulfobromophthalein in the blood plasma, after
conjugation of sulfobromophthalein with glutathione in
hepatocytes and transport of the conjugates from the
hepatocytes to the blood (Dubin and Johnson 1954;
Sprinz and Nelson 1954; Shani et al. 1970; Kondo et
al. 1974). Although this syndrome is rare (Takino et al.
1977), cholestasis is frequently induced by many kinds
of drugs (Farrell 1997; Sasabe et al. 1998) and is also
observed in pregnant women and newborns. The pu-
tative transporter for conjugated bilirubin is also ex-
pected to export other conjugated substrates, including
drugs, through the canalicular membrane. Identification
and analysis of the transporters provide valuable infor-
mation for understanding the pharmacokinetics of the
drugs. Moreover, the analysis and understanding of DJS
should lead to a better diagnosis and treatment of these
clinical problems.
Hepatobiliary excretion of conjugated bilirubin is me-
diated by an ATP-dependent transport system, a cana-
licular multispecific organic anion transporter (cMOAT)
(MIM 601107), in the apical (canalicular) membrane of
hepatocytes (Kitamura et al. 1990; Oude Elferink et al.
1990, 1995). The multidrug resistance–associated pro-
tein (MRP), another member of the ATP-binding cassette
(ABC)–transporter superfamily, can also transport glu-
tathione conjugates (leukotriene C4 and dinitrophenyl
glutathione ) (Cole et al. 1992; Loe et al. 1996; Keppler
et al. 1997). These glutathione conjugates are also pu-
tative substrates for transport by the cMOAT protein
(Cole et al. 1992; Loe et al. 1996), but the expression
of the MRP gene in the liver is very low (Cole et al.
1992).
We previously had isolated the humanMRP2/cMOAT
gene as the candidate transporter for the glucuronide-
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Table 1
Mutations in MRP2/cMOAT and Serum Total- and Direct-Bilirubin and Urinary Coproporphyrine Isomer I Fractions, in Patients with DJS
and in Their Families
PEDIGREE AND PATIENT/
FAMILY MEMBER ALTERATION IN cMAOT EXON PUTATIVE CONSEQUENCE
CONCENTRATION [NORMAL RANGE]a
T-bilirubin
[.3–1.0]
(mg/dl)
D-bilirubin
[.1–.6]
(mg/dl)
Urinary
Coproporphyrin
I Fraction [!27]b
(%)
1:
DJ1 2302(CrT)/2302(CrT) 18 R768W/R768W 5.0 3.8 NT
2:
DJ2 2302(CrT)/wild type 18 R768W/wild type NT NT 42.1
DJ3 24392(TrC)/wild type 18 Splice donor/wild type NT NT 43.5
DJ4 2302(CrT)/24392(TrC) 18 R768W/splice donor 1.3 .8 94.5
DJ5 2302(CrT)/24392(TrC) 18 R768W/splice donor 1.3 .8 93.6
DJ6 Wild type/wild type ) Wild type/wild type NT NT NT
3:
DJ7 18152(TrA)/18152(TrA) 13 Splice donor/splice donor 5.2 3.8 NT
4:
DJ8 2302(CrT)/2302(CrT) 18 R768W/R768W 4.8 3.2 NT
5:
DJ9 24392(TrC)/4145(ArG) 18/29 Splice donor/Q1382R 2.5 1.6 80.0
6:
DJ10 24392(TrC)/24392(TrC) 18 Splice donor/splice donor 2.1 1.6 85.7
DJ11 24392(TrC)/wild type 18 Splice donor/wild type .9 .4 48.0
DJ12 24392(TrC)/wild type 18 Splice donor/wild type .5 .2 36.9
a NT  not tested.
b Source: Frank et al. (1990).
and glutathione-conjugated antitumor agents (Taniguchi
et al. 1996) and had found that it is highly homologous
to the humanMRP gene (Bu¨chler et al. 1996; Taniguchi
et al. 1996; Kool et al. 1997). These results, together
with both the liver-specific expression of the gene and
its mapping to chromosome 10q24 (Taniguchi et al.
1996), suggest that it may be causative in DJS. Animal
models of DJS show a defect in the rat MRP2/cmoat
gene (Bu¨chler et al. 1996; Paulusma et al. 1996; Ito et
al. 1997). A putative cMOAT protein cross-reactingwith
the antibody against human MRP at the canalicular
membrane in the liver has not been observed in DJS
(Kartenbeck et al. 1996). Patients with DJS show DNA
sequence variations in the human MRP2/cMOAT gene
(Paulusma et al. 1997; Wada et al. 1998).
In the present study, we searched for additional mu-
tations in the MRP2/cMOAT gene in patients with DJS,
to complete a genotype-phenotype correlation. We first
determined the genomic structure of the human MRP2/
cMOAT gene and then used this information to identify
mutations in the genomic DNA of patients with DJS.
Our combined studies indicate that, except for one, all
the mutations identified are in the cytoplasmic domain
containing the first ATP-binding domain and the adja-
cent transmembrane domain.
Subjects and Methods
Subjects
Three patients with DJS (DJ8–DJ10) were analyzed
in this study. DJ8 is an 81-year-old Japanese man who
has been jaundiced since childhood. DJ9 is a 24-year-
old Japanese woman with a history of mild jaundice.
DJ10 is a 26-year-old Japanese woman. DJ11 and DJ12
are the father and mother, respectively, of DJ10 and are
not icteric and have had no abnormal laboratory find-
ings, except in the case of the urinary coproporphyrin
isomer I fraction (table 1). Findings from liver biopsy
and/or urinalysis were used for diagnosis. Light-micros-
copy examination of the liver specimens of all patients
showed that most of the hepatocytes contained pigment
granules. DJ8 underwent laparoscopic examination,
which showed that his liver was black. Table 1 shows
the plasma bilirubin concentration and urinary copro-
porphyrin I fraction of these patients with DJS. Other
laboratory findings for these three patients were within
normal limits. The serum levels of aspartate aminotrans-
ferase, alanine aminotransferase, alkaline phosphatase,
g-glutamyltranspeptidase, lactate dehydrogenase, and a-
fetoprotein were normal. Serum antibody titers showed
no evidence of infection with rubella virus, cytomega-
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Figure 1 Nucleotide sequence of cMOAT, around the proximal
ABC region. The nucleotide sequences of the primer pair G are in-
dicated by thick underlines and boldface “G5′” and “G3′.” Walker A,
Walker B, and active transporter-family signature (Walker C) motifs
are indicated by underlines and boldface “WA,” “WB,” and “WC,”
respectively. The 2302(CrT) transition detected in our previous and/
or present study is indicated by a boldface “T” below the wild-type
sequence Walker C. Amino acid change W is also indicated, as a
boldface “W,” above wild-type amino acid R. The deletion regions
generated by splicing mutations 1669del147 (in DJ7), 2272del168 (in
DJ3, DJ4, DJ5, DJ9, and DJ10) are circumscribed by boxes. Numbers
on the far right indicate nucleotide positions, numbered from the trans-
lation start site.
lovirus, hepatitis B virus, or herpes simplex. All human
samples were obtained under a protocol approved by
the institutional review board, with all subjects provid-
ing informed consent.
Reverse Transcriptase-PCR (RT-PCR)
For RT-PCR, primer pairs G (5′-TTGGCTGAGATT-
GGAGAGAAG-3′ and 5′-GAACTGCGGCTAAGTGT-
TCG-3′, for G5′ and G3′, respectively, in fig. 1) and K
(5′-GGCTGTTGAGCGAATAACTG-3′ and 5′-GCCT-
TCCAAATCTCCTCATC-3′) were used. Total RNA
from peripheral blood leukocytes and the liver tissue of
patients with DJS was isolated by use of ISOGEN (Nip-
pongene). First-strand synthesis from total RNA was
performed by use of random hexanucleotide primers and
Moloney murine leukemia–virus reverse transcriptase
(GIBCO BRL). The single-stranded cDNAwas amplified
by PCR with 2 pmol each of forward and reverse primer,
as described above, by use of AmpliTaq Gold DNA
polymerase (Perkin-Elmer). For PCR, 40 cycles of de-
naturation (94C for 30 s), annealing (60C for 30 s),
and extension (72C for 45 s) were performed.
Amplification of Genomic DNA
Samples of genomic DNA were prepared from pe-
ripheral blood leukocytes by standard methods, and ta-
ble 2 shows the nucleotide sequences of the primers. The
primer pairs used to amplify the genomic fragments con-
taining each exon and splice junction were designed by
comparison of the cMOAT cDNA sequence (Taniguchi
et al. 1996; GenBank) with the partial genomic sequence
determined in the present study (see Results). With these
primers for PCR, 40 cycles of denaturation (94C for
30 s), annealing (60C for 30 s), and extension (72C for
45 s) were performed.
Sequencing and Identification of Mutations
We sequenced PCR or RT-PCR products, either di-
rectly or after the subcloning, by using a Big-Dye Ter-
minator Cycle Sequencing kit (Applied Biosystems) and
a DNA sequencing system (model 377; Applied Bio-
systems). Both sense and antisense strands were se-
quenced, for confirmation.
Results
Genomic Organization of the Human MRP2/cMOAT
Gene
We obtained nine clones by screening a human pla-
cental genomic library in lEMBL3, using, as probes,
cDNA fragments covering the entire region of human
MRP2/cMOAT. Partial sequencing of these clones by
means of primers designed from and compared with the
MRP2/cMOAT cDNA sequence (Taniguchi et al. 1996;
GenBank) indicated that the human MRP2/cMOAT
gene spans 200 kb of genomic DNA containing 32
exons (fig. 2). All exons were flanked by the dinucleo-
tides GT and AG, consistent with the consensus se-
quences for splice junctions in eukaryotic genes (Breath-
nach and Chambon 1981) (table 3). Exon 1 contained
a 5′ UTR and 33 bp of coding sequence, whereas exon
32 consisted of a 130-bp coding sequence and a 3′ UTR.
The exon-splitting pattern of the MRP2/cMOAT gene,
especially for the ABC, the adjacent region, and the pos-
terior half of the gene, was similar to that in the human
MRP gene (Grant et al. 1997) (fig. 2), suggesting a close
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Table 2
Sequences of PCR Primer Pairs Used to Amplify Genomic DNA
Primer
Pair Primer 1 Primer 2
Amplified
Exon
M1G/1 5′-TTGTTGGCCAGCTCTGTTG-3′ 5′-GTTCTTGTTGGTGACCACCC-3′ 1
M1G/2 5′-AAAGCAGTGGGATGTGCTG-3′ 5′-TGTCTCTACTGTGCACCAAGG-3′ 2
M1G/3 5′-CACCGGAAACCATTCTGTTC-3′ 5′-TTTGCCTCACTATGGATCCC-3′ 3
M1G/4 5′-TCACGACAGTCTCCTCCCTC-3′ 5′-CCAAAGGAAGTCTACATGGCC-3′ 4
M1G/5 5′-ACATGAGGAGGTACCATGGG-3′ 5′-GGATCCAGCCAATCCAATAC-3′ 5, 6
M1G/6 5′-GGTGGAGATAGCCTCTGACC-3′ 5′-TGCACTGAGAAGTATGAAGTGC-3′ 7
M1G/7 5′-CCTGTACAGAGAAGGCCACG-3′ 5′-CGGTCTTCATGACACAATGC-3′ 8
M1G/8 5′-GGCTTTGGACAATTCTGGTC-3′ 5′-TCCACCCATTGTCTGTGAAC-3′ 9
M1G/9 5′-AGGCAAGAAGTCACAGTGCC-3′ 5′-TTGCCCAAACTCCCATTAAG-3′ 10
M1G/10 5′-ACAGTCAGGCAAGGGCTATG-3′ 5′- TCCTTACCCACAGAGAGCC-3′ 11
M1G/11 5′-ATCAGATACACCTGGTGCCC-3′ 5′-TCTTGCGGTCAGGCCTANAG-3′ 12
M1G/12 5′-GGAGGCTGGATGATCCTTAAG-3′ 5′-TAGCAGTGAGAATGCCGACC-3′ 13
M1G/13 5′-TGATCCTTAAGGCGCCTTC-3′ 5′-CTGCAGGTCAACGATCTCTC-3′ 14
M1G/14 5′- CTGATGGAGAAAGCGGAGAG-3′ 5′-CATGGCAAATCCAGTATCAGG-3′ 15
M1G/15 5′-CCCTGCTATCTCCTTCAAAGAC-3′ 5′-GCTGAAATGGGAAGGAGAATC-3′ 16
M1G/16 5′-GATCCTCAGTCATCCTGATGC-3′ 5′-ACATGGAATATTGTGGCCAC-3′ 17
M1G/17 5′-TCACAGGGTGACAAGCAAC-3′ 5′-TTTACCATTCCACCCATGGC-3′ 18, 19
M1G/18 5′-GTGTCTCCCTAGTCCATGATGG-3′ 5′-TCACTCAGCTGGCATCAAAG-3′ 20
M1G/19 5′-TGACTGTGACATCTGCTTGC-3′ 5′-GGACAGAGGACATATTGCTCC-3′ 21
M1G/20 5′-TCCACTTTCTCCTTGTGGTTG-3′ 5′-CCTCCCTGTCAGAAAGATCC-3′ 22, 23
M1G/21 5′- AAGGAGTTCTGGGAACACCAC -3′ 5′- TTCTCAGGAAAGAGGCTGGG -3′ 24
M1G/22 5′-GGAGCCTCTCATCATTCTGC-3′ 5′-TTTCACACCACTAGCCATGC-3′ 25
M1G/23 5′-GAGGCATTGCCTAAGAGTGC-3′ 5′-AAAGATGGAGCCAGGGTTTG-3′ 26
M1G/24 5′- TTGGTTTCTGTGCCTATGATG -3′ 5′- AATGATGAAGGCTTAGGGCC -3′ 27, 28
M1G/25 5′-AGAGATGGAGTAGCCAGTCAC-3′ 5′-CAGCCACAAATGCATATTACC-3′ 29
M1G/26 5′-AAGCTCAACCACAAACCAGC-3′ 5′-ATTCTATGCCAGGCATCACC-3′ 30
M1G/28 5′- CCTGCGTCTTTCCTTGGTC-3′ 5′-AAACCTTCTGCCATCAGGTG –3′ 31
M1G/27 5′-CCTTGTTTCAGGGTAATGGTC-3′ 5′-CAGGACAGTGGTTGTCCC-3′ 32
evolutionary relationship between these ABC-trans-
porter genes.
Mutation Detection in the Human MRP2/cMOAT
Gene in Patients with DJS
To identify mutations in the MRP2/cMOAT gene in
patients with DJS, we designed primer pairs (see Subjects
and Methods) (table 2) that cover the entire MRP2/
cMOAT cDNA and exon-intron junction regions. By
using PCR and DNA-sequence analysis, we analyzed the
MRP2/cMOAT genes from three patients, DJ8–DJ10,
and from the parents of DJ10 (DJ11 and DJ12). These
patients are unrelated to each other. The first alteration
was a homozygous missense mutation 2302(CrT) in
DJ8 (fig. 1 and table 1), which has been identified in
three other patients—DJ1, DJ4, and DJ5 (Wada et al.
1998)—who are unrelated to DJ8. Both children, DJ4
and DJ5, are heterozygous for the mutation. This alter-
ation was accompanied by an amino acid substitution,
R768W, in the active transporter-family signature (Hig-
gins 1992) (fig. 1).
In DJ10 we identified the homozygous mutation
24392(TrC), a TrC transition of two bases after the
3′ boundary of the exon 18 (fig. 1 and table 1). This
second mutation was also observed in patients DJ4 and
DJ5 and in their mother, DJ3 (Wada et al. 1998) (table
1). The direct sequence of the genomic DNA in DJ10
and in her parents, DJ11 and DJ12, showed a hetero-
zygous state for the mutation in DJ11 and DJ12, as well
as perfect cosegregation of the mutation with the DJS
trait (table 1). The mutation 24392(TrC) was found
at the conserved splice-donor site, and we predicted that
this mutation would cause a deletion of 168 nucleotides,
at nucleotide positions 2272–2439, in cDNA (see
below).
In DJ9 we identified two mutations, 24392(TrC),
the same as the mutation identified in DJ10, and an ArG
transition at nucleotide position 4145 (table 1). The
24392(TrC) mutation was identified in DJ9. These
second and third mutations are heterozygous in DJ9.
The third alteration resulted in amino acid substitution
Q1382R in the position at the ABC region. The
base substitutions 2302(CrT), 24392(TrC), and
4145(ArG) were not detected in any of 50 unrelated
normal volunteers.
mRNA Analysis for Splice-Site Mutations
We confirmed the mutations 2302(CrT) and
4145(ArG) in the MRP2/cMOAT cDNA in DJ8 and
DJ9, respectively, by RT-PCR and DNA sequencing us-
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Figure 2 Comparison of exon-splitting pattern, between MRP2/cMOAT and its related gene, MRP (Grant et al. 1997). Exons are
represented by unshaded boxes, and splice sites are indicated by vertical lines. The exon number for each gene is shown both above and below.
The highly conserved motifs—Walker A, Walker B, and Walker C—in an ABC are denoted as “WA,” “WB,” and “WC,” respectively. Shaded
boxes indicate the exons coding the ABC. Predicted membrane-spanning domains are indicated by horizontal bars (MSD1, MSD2, and MSD3)
(Deeley and Cole 1997; Hipfner et al. 1997; Tusnady et al. 1997). Regions in which the two genes show exactly identical splitting are indicated
by vertical dashed lines.
ing primer pairs G and K (see Subjects and Methods)
and mRNA extracted from peripheral blood lympho-
cytes (data not shown). To determine whether the
24392(TrC) mutation might cause splicing alteration
and deletion of the MRP2/cMOAT gene, lymphocyte
RNA from DJ10 was isolated and analyzed by RT-PCR.
A 500-bp product was detected in control individuals,
whereas a 332-bp product was detected in DJ10 by RT-
PCR analysis using primer pair G (see Subjects and
Methods and fig. 1). Sequence analysis of the 332-bp
product showed the expected deletion of 168 nucleotides
(fig. 1).
Discussion
We previously had reported mutations of the MRP2/
cMOAT gene in patients with DJS and had suggested
that the MRP2/cMOAT gene is responsible for the de-
fects in patients with DJS (Wada et al. 1998). In the
present study, we have identified other mutations, in-
cluding two new ones. The first mutation, identified in
DJ8 in the present study, is 2302(CrT) and is associated
with the amino acid change Arg768rTrp (R768W) in the
highly conserved domain, the Walker C motif. This mu-
tation is the same as that which we previously had iden-
tified in patients DJ1, DJ4, and DJ5. Patients DJ4 and
DJ5 are brothers, but the other patients are not related
to each other. Among the seven patients analyzed, this
mutation was identified in four individuals, suggesting
the presence of a founder effect. The second mutation
is a homozygous TrC transition in patient DJ10, found
two bases after the 3′ boundary of exon 18 (the splice-
donor site). The third mutation is 4145(ArG), which
predicts amino acid change Gln1382rArg (Q1382R)
within the ABC at the carboxyl-terminal end. This same
amino acid substitution in the ABC is in the cystic fi-
brosis transmembrane conductance regulator gene
(CFTR) in patients with cystic fibrosis (Do¨rk et al. 1994),
suggesting that this mutation could affect the function
of MRP2/cMOAT. These second and third mutations
were in a compound-heterozygous state in DJ9.
Interestingly, all the mutations observed in the patients
with DJS were localized within the ABC or its adjacent
regions. This tendency might be due to the absence of
any functional effect in any mutation occurring outside
the ABC and its adjacent domain for cMOAT, leading
to no alteration of phenotype. The existence of several
polymorphisms in other domains (i.e., besides the ABC
region) of other ABC transporters, such as CFTR (Cystic
Fibrosis Mutation Data Base) or ABCR (Allikmets et al.
1997), is consistent with this possibility. With the CFTR
gene, ∼80% of mutations in patients are identified
within the ABC region, and almost all of them cause a
severe form of the disease (Welsh and Smith 1993), sug-
gesting that alteration in the ABC could impair the trans-
porter activity. Site-directed mutagenetic analysis of P-
glycoprotein, which is another member of the ABC-
transporter superfamily, showed that the transmem-
brane domain is important for substrate specificity but
not for the transporter activity itself (Gottesman et al.
1995; Taguchi et al. 1997). Mutations localized around
the ABC thus might disrupt the function of the trans-
porter, not only in CFTR and P-glycoprotein but also in
MRP2/cMOAT. By contrast, mutations in the trans-
membrane domain could change the specificities for their
substrates but might not completely disrupt their trans-
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Table 3
Exon-Intron Organization of the Human cMOAT Gene
Exon 3′ Acceptor Exon 5′ End
Exon Size
(bp) Exon 3′ End 5′ Donor
1 Not determined 5′ UTR33 TTTTGG gtgaga
2 ctccag AATTCC 174 AAGCAG gtaaag
3 tctcag GTATTC 126 ACATGG gtaaga
4 ctccag CTCCTG 135 TTACAG gtaagg
5 tcatag GGTGAC 108 TCAAAT gtgaga
6 tttcag AATCCA 56 TGACAG gtagga
7 ttccag CATCAT 235 GTCCTG gtaact
8 acctag GAAGAT 164 GCTGAA gtgagt
9 tggcag ATTGCT 178 AAGAAG gtaagc
10 ctttag GCATTG 255 ATTCAG gtaaag
11 tggcag GTCAAA 66 ATCAAG gtgaga
12 tattag ATCCTG 138 GTCCTG gtgagt
13 ttccag GTATCT 147 CTCCAG gtaggt
14 ctctag GCCAGT 85 ATTTTG gtaaat
15 caacag ACAAAG 67 CCGAGA gtgagt
16 tttcag TGTGAA 127 ATCAAG gtgaga
17 atctag GGCACC 177 GAGAAG gtactt
18 cttcag GGTATA 168 GGCAAG gtgaga
19 ttatag ACTCGA 181 CCACAG gtatgt
20 ccgcag TCCATG 127 CCGCAG gttggc
21 tctcag TTCTAG 136 GGAAAG gtgaac
22 ttgcag GTGAAG 220 CCCAAG gtatgt
23 ctctag GTATAT 155 GCCGGC gtaagt
24 tcctag GATATT 156 GTTCAG gtaggt
25 gtccag ATGTTT 200 CAACAG gtgagg
26 ccacag GTGGCT 127 CTCAAT gtgagc
27 ctgtag ATCACA 102 AATGAG gtaagg
28 tgccag GCACCC 144 GAGAAG gtaggt
29 tcgcag ATTGGT 159 CCCCAG gtgagc
30 ttgcag GACCCC 167 CCTGAG gtaatg
31 ctgcag CATAGG 195 TGACAA gtgagt
32 tttcag GGTAAT 1303′ UTR Not determined
NOTE.—Exon sequences and intron sequences are shown as uppercase letters and
lowercase letters, respectively.
porter activities. However, further identification of mu-
tations in MRP2/cMOAT is necessary to confirm this
possibility.
Table 1 summarizes the mutations that we identified
in the patients with DJS. The serum bilirubin concen-
tration and the proportion of urinary coproporphyrin
isomer I in these patients have been determined. It will
be important to learn whether the level of bilirubin con-
centration is dependent primarily on each specific mu-
tation. According to the report by Kondo et al. (1974),
the serum bilirubin concentration in 40 patients with
DJS was 1.3–6.9 mg/dl. We identified homozygous mu-
tation 2302(CrT) in DJ1 and DJ8, whose bilirubin con-
centration was 5.0 mg/dl and 4.8 mg/dl, respectively,
concentrations near the higher end of the range described
by Kondo et al. (1974). This mutation is accompanied
by an amino acid substitution, R768W, in the Walker C
motif, which is a highly conserved domain among the
ABC-transporter family. This mutation might cause se-
vere disruption of the transporter activity and, conse-
quently, shows a relatively high serum bilirubin
concentration in DJS. A high bilirubin level similar to
that observed in DJ1 and DJ8 was observed in DJ7,
whose mutation in MRP2/cMOAT was 18152(TrA).
This mutation causes abnormal splicing and, conse-
quently, a 147-bp deletion in MRP2/cMOAT cDNA,
without an immature stop codon. This deletion of the
ABC region likely reduces the level of normal cMOAT
protein and its activity. The absence of cMOAT in the
liver of DJ7 was confirmed by immunohistochemical
analysis (data not shown).
The urinary coproporphyrin isomer I fraction was ex-
amined in several patients and their family members. All
of the patients with DJS showed 180% of urinary co-
proporphyrin isomer I fraction, whereas normal controls
showed !27% (Frank et al. 1990). Interestingly, all ex-
amined family members who carry a heterozygous mu-
tation in the MRP2/cMOAT gene (i.e., individuals DJ2,
DJ3, DJ11, and DJ12) showed the normal range of T-
and D-bilirubin levels, whereas they showed levels of
urinary coproporphyrin isomer I fraction that were
slightly higher than the normal range of !27% (table
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1). The mechanisms for abnormal coproporphyrin iso-
mer I fraction in the urine are unknown, but a corre-
lation may exist between the urinary coproporphyrin
isomer I level and the homozygous/heterozygous status
of mutation in the MRP2/cMOAT gene. In Japan, the
expected number of people carrying a heterozygous mu-
tation in MRP2/cMOAT is 200,000, which is calcu-
lated on the basis of the frequency of patients with
DJS—that is, 121/100,000,000 people in a nationwide
survey in Japan (Takino et al. 1977; Vogel andMotulsky
1997, pp. 129–162). The transport and/or pharmaco-
kinetics of some substrates might be affected by a het-
erozygous mutation in the MRP2/cMOAT gene, and a
putative differential responsiveness to some drugs and
their side effects in these carriers might be also an im-
portant clinical factor. Further study is needed for an
understanding of how MRP2/cMOAT maintains a
steady state of the levels of bilirubin and coproporphyrin
isomer I in patients with DJS.
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